Mr Nicholas Connor

Int Head of Res Governance & Integrity

United Kingdom

Nicholas has over 15 years of experience in cutting-edge Global Health research spanning diverse projects and settings. He has worked in the Indian Sub-Continent for many years as well as worked intensively on projects in a variety of East, West and Central African countries. He has deep experience with development, execution and management of complex projects. He has worked with the school since 2019 managing Quality Assurance for a number of clinical trials on Ebola and HPV vaccines. He has deep experience researching risk factors predisposing young children to community-acquired neonatal infections in South Asia and has been involved in child nutrition research and anthropometry. Nicholas is a team player and continues to help generate policy-changing research to optimally safeguard and improve the health of people in vulnerable conditions, to minimize threats to healthcare systems and to help build research capacity in LMICs.

Nicholas holds degrees with distinction in Global Health, Health Sciences and Ethics. He is focused on the set-up and maintenance of quality assurance, control and management systems to support Good Clinical Practices (ICH-GCP) during collaborative research in complex environments. He has a long-term interest in research ethics, development economics, data science, South-south partnerships and global health history.


Executive Office
Professional Support Services


Nicholas has taught numerous short courses in Good Clinical Practice, Good Clinical Laboratory Practices, Issue Escalation within a clinical trial and has developed a suite of training materials related to these topics.
Formerly, he developed and taught a course module in Barts and The London School of Medicine and Dentistry in Rheumatology for the undergraduate medical students while at Queen Mary University London.
Nicholas underwent course development training at Harvard School of Public Health to develop course content for the Global Health Delivery Project at Harvard University, this course was cancelled due to the 2008 financial downturn.
He remains interested in global health Pedagogy.


Quality Assurance in Global Health; Clinical Trials; Neonatal Infection; Ebola Virus Disease/viral hemorrhagic fevers;
Research Area
Clinical trials
Quality improvement
Capacity development
Disease and Health Conditions
Human papillomavirus (HPV)
Emerging infectious diseases
Sierra Leone
Sub-Saharan Africa (developing only)
South Asia

Selected Publications

Immunogenicity and Safety of One-Dose Human Papillomavirus Vaccine Compared With Two or Three Doses in Tanzanian Girls (DoRIS): An Open-Label, Randomised, Non-inferiority Trial
WATSON-JONES, D; Changalucha, J; WHITWORTH, H; Pinto, L; Mutani, P; Indangasi, J; Kemp, T; Hashim, R; Kamala, B; Wiggins, R; Songoro, T; CONNOR, N; Mbwanji, G; Pavon, MA; Lowe, B; Mmbando, D; KAPIGA, S; MAYAUD, P; De SanJosé, S; Dillner, J; HAYES, RJ; Lacey, CJ; Baisley, K;
Obstetrical & Gynecological Survey
Risk factors for community-acquired bacterial infection among young infants in South Asia: a longitudinal cohort study with nested case-control analysis.
CONNOR, NE; Islam, MS; Mullany, LC; Shang, N; Bhutta, ZA; Zaidi, AK M; Soofi, S; Nisar, I; Panigrahi, P; Panigrahi, K; Satpathy, R; Bose, A; Isaac, R; Baqui, AH; Mitra, DK; Sadeq-Ur Rahman, Q; Hossain, T; Schrag, SJ; Winchell, JM; Arvay, ML; Diaz, MH; Waller, JL; Weber, MW; Hamer, DH; Hibberd, P; ... Saha, SK.
BMJ global health
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.
MANNO, D; Bangura, A; Baiden, F; Kamara, AB; AYIEKO, P; Kallon, J; Foster, J; Conteh, M; CONNOR, NE; Koroma, B; Njie, Y; Borboh, P; Keshinro, B; Lawal, BJ; KROMA, MT; Otieno, GT; Deen, AT; CHOI, EM-L; BALAMI, AD; Gaddah, A; McLean, C; Luhn, K; Adetola, HH; Deen, GF; Samai, M; ... WATSON-JONES, D.
The Lancet. Infectious diseases
Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial.
WATSON-JONES, D; Changalucha, J; WHITWORTH, H; Pinto, L; Mutani, P; Indangasi, J; Kemp, T; Hashim, R; Kamala, B; Wiggins, R; Songoro, T; CONNOR, N; Mbwanji, G; Pavon, MA; Lowe, B; Mmbando, D; KAPIGA, S; MAYAUD, P; De SanJosé, S; Dillner, J; HAYES, RJ; Lacey, CJ; BAISLEY, K;
The Lancet Global health
Infectious aetiologies of neonatal illness in south Asia classified using WHO definitions: a primary analysis of the ANISA study.
Arvay, ML; Shang, N; Qazi, SA; Darmstadt, GL; Islam, MS; Roth, DE; Liu, A; CONNOR, NE; Hossain, B; Sadeq-Ur Rahman, Q; El Arifeen, S; Mullany, LC; Zaidi, AK M; Bhutta, ZA; Soofi, SB; Shafiq, Y; Baqui, AH; Mitra, DK; Panigrahi, P; Panigrahi, K; Bose, A; Isaac, R; Westreich, D; Meshnick, SR; Saha, SK; ... Schrag, SJ.
The Lancet Global Health
Validation of community health worker identification of maternal puerperal sepsis using a clinical diagnostic algorithm in Bangladesh and Pakistan.
LeFevre, AE; Mir, F; Mitra, DK; Ariff, S; Mohan, D; Ahmed, I; Sultana, S; Winch, PJ; Shakoor, S; CONNOR, NE; Islam, MS; El-Arifeen, S; Quaiyum, MA; Baqui, AH; Gravett, MG; Santosham, M; Bhutta, ZA; Zaidi, A; Saha, SK; Ahmed, S; Soofi, S; Bartlett, LA;
Journal of global health
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
ISHOLA, D; Manno, D; AFOLABI, MO; Keshinro, B; Bockstal, V; Rogers, B; Owusu-Kyei, K; Serry-Bangura, A; Swaray, I; Lowe, B; Kowuor, D; BAIDEN, F; Mooney, T; Smout, E; Köhn, B; Otieno, GT; Jusu, M; Foster, J; Samai, M; Deen, GF; LARSON, H; LEES, S; Goldstein, N; Gallagher, KE; Gaddah, A; ... EBL3001 study group,
Lancet Infectious Diseases
Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries.
Badio, M; Lhomme, E; Kieh, M; Beavogui, AH; Kennedy, SB; Doumbia, S; Leigh, B; Sow, SO; Diallo, A; Fusco, D; Kirchoff, M; Termote, M; Vatrinet, R; Wentworth, D; Esperou, H; Lane, HC; Pierson, J; Watson-Jones, D; Roy, C; D'Ortenzio, E; GREENWOOD, B; Chêne, G; Richert, L; Neaton, JD; Yazdanpanah, Y; ... PREVAC study team,
Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study.
Wang, X; Li, Y; O'Brien, KL; Madhi, SA; Widdowson, M-A; Byass, P; Omer, SB; Abbas, Q; Ali, A; Amu, A; Azziz-Baumgartner, E; Bassat, Q; Abdullah Brooks, W; Chaves, SS; Chung, A; Cohen, C; Echavarria, M; Fasce, RA; Gentile, A; Gordon, A; Groome, M; Heikkinen, T; Hirve, S; Jara, JH; Katz, MA; ... Respiratory Virus Global Epidemiology Network,
The Lancet Global health
Causes and incidence of community-acquired serious infections among young children in south Asia (ANISA): an observational cohort study.
Saha, SK; Schrag, SJ; El Arifeen, S; Mullany, LC; Shahidul Islam, M; Shang, N; Qazi, SA; Zaidi, AK M; Bhutta, ZA; Bose, A; Panigrahi, P; Soofi, SB; CONNOR, NE; Mitra, DK; Isaac, R; Winchell, JM; Arvay, ML; Islam, M; Shafiq, Y; Nisar, I; Baloch, B; Kabir, F; Ali, M; Diaz, MH; Satpathy, R; ... Baqui, AH.
See more information